Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Phase II Cladribine Add-on to Interferon-beta (IFN-b) Therapy in MS Subjecs With Active Disease (ONWARD)
Saccadic intrusions: review and update.
Emerging roles of endothelial cells in multiple sclerosis pathophysiology and therapy.
Autologous attenuated T-cell vaccine (Tovaxin) dose escalation in multiple sclerosis relapsing-remitting and secondary progressive patients nonresponsive to approved immunomodulatory therapies.
Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis.
Dalfampridine may activate latent trigeminal neuralgia in patients with multiple sclerosis.
A complex role of herpes viruses in the disease process of multiple sclerosis.
Rescue Therapy Using Rituximab for Multiple Sclerosis.
The multiple sclerosis rating scale, revised (MSRS-R): Development, refinement, and psychometric validation using an online community.
Effects of idebenone (CV-2619) and its metabolites on respiratory activity and lipid peroxidation in brain mitochondria from rats and dogs.
Transverse myelitis -- a review of the presentation, diagnosis, and initial management.
B-07The Cognitive Health Questionnaire: Initial Psychometric Data in a Multisite Multiple Sclerosis Sample.
Targeting blood-brain barrier sphingolipid signaling reduces basal P-glycoprotein activity and improves drug delivery to the brain.
Rituximab in Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome.
Specific peripheral B cell tolerance defects in patients with multiple sclerosis.
Antiviral drug ganciclovir is a potent inhibitor of microglial proliferation and neuroinflammation.
Novartis gains approval for Gilenya® as a first-line disease modifying oral therapy for multiple sclerosis in Switzerland and Australia
Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis.
Cardiotoxicity of mitoxantrone treatment in a german cohort of 639 multiple sclerosis patients.
Safety issue puts daclizumab in doubt for MS
Mechanisms of neurodegeneration shared between multiple sclerosis and Alzheimer's disease.
JC virus antibody index in natalizumab-treated patients: correlations with John Cunningham virus DNA and C-reactive protein level.
Modeling probability of additional cases of natalizumab-associated JCV sero-negative progressive multifocal leukoencephalopathy.
Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain.
A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) (LIBRETTO)

Pages